JOP20220012A1 - مشتقات n-ميثيل، n-(6-(ميثوكسي) بيريدازين-3- يل) أمين كعوامل تعديل أتوتوتاكسين (atx) لمعالجة التهاب المجاري الهوائية أو الأمراض التليفية - Google Patents

مشتقات n-ميثيل، n-(6-(ميثوكسي) بيريدازين-3- يل) أمين كعوامل تعديل أتوتوتاكسين (atx) لمعالجة التهاب المجاري الهوائية أو الأمراض التليفية

Info

Publication number
JOP20220012A1
JOP20220012A1 JOP/2022/0012A JOP20220012A JOP20220012A1 JO P20220012 A1 JOP20220012 A1 JO P20220012A1 JO P20220012 A JOP20220012 A JO P20220012A JO P20220012 A1 JOP20220012 A1 JO P20220012A1
Authority
JO
Jordan
Prior art keywords
pyridazin
methoxy
methyl
autotaxin
atx
Prior art date
Application number
JOP/2022/0012A
Other languages
English (en)
Inventor
Christian Andreas Kuttruff
Cédrickx Godbout
Tom Bretschneider
Gerald Juergen Roth
Hannes Fiepko Koolman
Domnic Martyres
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of JOP20220012A1 publication Critical patent/JOP20220012A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

يتعلق الاختراع الحالي بمشتقات N-(6-(ميثوكسي) بيريدازين-3- يل) أمين كعوامل تعديل أتوتوتاكسين (ATX) لمعالجة التهاب المجاري الهوائية أو الأمراض التليفية مثل على سبيل المثال مرض الرئة مجهول السبب (IFF) أو التصلب اللويحي (SSc). يكشف الوصف الحالي عن تحضير المركبات النموذجية (على سبيل المثال الصفحات 57 إلى 75؛ الأمثلة 1.1 إلى 5) بالإضافة إلى بياناتها الحيوية ذات الصلة (على سبيل المثال الصفحات 15 إلى 21؛ الجداول 1 إلى 9). يكون أحد المركبات النموذجية على سبيل المثال 1-(6-(4-(((6-((6-(تراي فلورو ميثيل) بيريدين-3-يل) ميثوكسي) بيريدازين-3-يل) أمينو) ميثيل) فينيل)-2، 6- داي آزا سبيرو [3.3] هبتان-2- يل) إيثان-1- أون (المثال 1.1).
JOP/2022/0012A 2019-07-22 2020-07-21 مشتقات n-ميثيل، n-(6-(ميثوكسي) بيريدازين-3- يل) أمين كعوامل تعديل أتوتوتاكسين (atx) لمعالجة التهاب المجاري الهوائية أو الأمراض التليفية JOP20220012A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19187617 2019-07-22
PCT/EP2020/070547 WO2021013830A1 (en) 2019-07-22 2020-07-21 N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (atx) modulators for the treatment of inflammatory airway or fibrotic diseases

Publications (1)

Publication Number Publication Date
JOP20220012A1 true JOP20220012A1 (ar) 2023-01-30

Family

ID=67438402

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0012A JOP20220012A1 (ar) 2019-07-22 2020-07-21 مشتقات n-ميثيل، n-(6-(ميثوكسي) بيريدازين-3- يل) أمين كعوامل تعديل أتوتوتاكسين (atx) لمعالجة التهاب المجاري الهوائية أو الأمراض التليفية

Country Status (25)

Country Link
US (2) US11485727B2 (ar)
EP (2) EP4364805A2 (ar)
JP (2) JP2022541065A (ar)
KR (1) KR20220038438A (ar)
CN (1) CN114206876B (ar)
AR (1) AR119453A1 (ar)
AU (1) AU2020316643A1 (ar)
BR (1) BR112021026887A2 (ar)
CA (1) CA3145868A1 (ar)
CL (1) CL2022000112A1 (ar)
CO (1) CO2022000243A2 (ar)
CR (1) CR20220022A (ar)
DK (1) DK4003998T3 (ar)
DO (1) DOP2022000008A (ar)
EC (1) ECSP22003856A (ar)
FI (1) FI4003998T3 (ar)
IL (1) IL289788A (ar)
JO (1) JOP20220012A1 (ar)
LT (1) LT4003998T (ar)
MA (1) MA56631B1 (ar)
MX (1) MX2022000958A (ar)
PE (1) PE20220964A1 (ar)
PT (1) PT4003998T (ar)
TW (1) TW202120492A (ar)
WO (1) WO2021013830A1 (ar)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020089098A1 (en) 2018-10-29 2020-05-07 Boehringer Ingelheim International Gmbh Novel pyridazines
US11465982B2 (en) 2019-07-22 2022-10-11 Boehringer Ingelheim International Gmbh Pyridazines
KR102587919B1 (ko) * 2022-07-22 2023-10-11 주식회사 넥스트젠바이오사이언스 신규한 헤테로사이클릭 화합물 및 이를 포함하는 오토탁신 저해용 약학 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007003580A1 (es) * 2006-12-11 2009-03-27 Boehringer Ingelheim Int Compuestos derivados de piridazina, antagonistas de mch; composicion farmaceutica que comprende a dicho compuesto; procedimiento de preparacion; y uso del compuesto en el tratamiento de trastornos metabolicos y/o trastornos alimentarios como obesidad, bulimia, anorexia, hiperfagia, diabetes.
TW200944520A (en) * 2008-01-29 2009-11-01 Glaxo Group Ltd Spiro compounds as NPY Y5 receptor antagonists
EP2771325B1 (en) * 2011-10-28 2017-06-28 Inhibitaxin Limited Pyridazine derivatives useful in therapy
PT2970255T (pt) 2013-03-14 2017-09-05 Galapagos Nv Compostos e as suas composições farmacêuticas para o tratamento de doenças inflamatórias
US9796719B2 (en) 2013-06-19 2017-10-24 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201503141D0 (en) * 2015-02-03 2015-04-08 Fosbel Inc Integral self-supporting refractory checker brick modules for glass furnace regenerator structures, and methods of forming same
GB201603745D0 (en) * 2016-03-04 2016-04-20 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
WO2017192304A1 (en) * 2016-05-02 2017-11-09 Inception 1, Inc. Arylcarboxamides and uses thereof
KR101798840B1 (ko) * 2017-05-17 2017-11-17 주식회사 레고켐 바이오사이언스 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물
BR112020027051A2 (pt) * 2018-07-27 2021-03-30 Mitsubishi Tanabe Pharma Corporation Derivados de piridina 3,5-dissubstituída e piridazina 3,5-dissubstituída e uso farmacêutico dos mesmos
WO2020089098A1 (en) 2018-10-29 2020-05-07 Boehringer Ingelheim International Gmbh Novel pyridazines
US11465982B2 (en) 2019-07-22 2022-10-11 Boehringer Ingelheim International Gmbh Pyridazines
KR20220035950A (ko) 2019-07-22 2022-03-22 베링거 인겔하임 인터내셔날 게엠베하 염증성 기도 질환 또는 섬유성 질환의 치료를 위한 오토탁신 (atx) 조절제로서의 n-메틸, n-(6-(메톡시)피리다진-3-일) 아민 유도체

Also Published As

Publication number Publication date
MA56631B1 (fr) 2024-05-31
EP4003998B1 (en) 2024-03-27
CN114206876B (zh) 2024-05-14
KR20220038438A (ko) 2022-03-28
CO2022000243A2 (es) 2022-01-17
JP2023116436A (ja) 2023-08-22
CL2022000112A1 (es) 2022-10-21
BR112021026887A2 (pt) 2022-04-26
PE20220964A1 (es) 2022-06-10
FI4003998T3 (fi) 2024-04-24
CN114206876A (zh) 2022-03-18
US11485727B2 (en) 2022-11-01
IL289788A (en) 2022-03-01
CR20220022A (es) 2022-03-02
AU2020316643A1 (en) 2022-02-17
EP4003998A1 (en) 2022-06-01
US20210024495A1 (en) 2021-01-28
DK4003998T3 (da) 2024-06-10
CA3145868A1 (en) 2021-01-28
JP2022541065A (ja) 2022-09-21
PT4003998T (pt) 2024-04-26
AR119453A1 (es) 2021-12-22
WO2021013830A1 (en) 2021-01-28
US20230100516A1 (en) 2023-03-30
EP4364805A2 (en) 2024-05-08
DOP2022000008A (es) 2022-03-15
MX2022000958A (es) 2022-02-14
ECSP22003856A (es) 2022-02-25
TW202120492A (zh) 2021-06-01
LT4003998T (lt) 2024-05-10

Similar Documents

Publication Publication Date Title
JOP20220012A1 (ar) مشتقات n-ميثيل، n-(6-(ميثوكسي) بيريدازين-3- يل) أمين كعوامل تعديل أتوتوتاكسين (atx) لمعالجة التهاب المجاري الهوائية أو الأمراض التليفية
MX2022000955A (es) Derivados de n-(6-metoxi)pirizadin-3-il) amina, n-metilo como moduladores de autotaxina (atx) para el tratamiento de enfermedades inflamatorias de las vias respiratorias o fibroticas.
NZ592685A (en) Modulators of cystic fibrosis transmembrane conductance regulator
WO2020140005A3 (en) 1 h-pyrrolo[2,3-b]pyridine derivatives and related compounds as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
MX2022000956A (es) Derivados de 1-(6-(metoxi)piridazin-3-il)ciclopropan-1-carboxamida como moduladores de autotaxina (atx) para el tratamiento de enfermedades inflamatorias de las vias respiratorias.
SMT201300098B (it) Forme solide di N-(4-(7-azabiciclo[2.2.1]eptan-7-il)-2-(trifluorometil)fenil-4-osso-5-trifluorometil)-1,4-diidrochinolina-3-carbossammide
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
EA200400953A1 (ru) Замещённые пиридиноны в качестве модуляторов map-киназы p38
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
CA2564990A1 (en) Morpholine compounds
TW200724136A (en) Pharmaceutical compositions comprising PPAR modulator
NZ591712A (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
UA86617C2 (en) 2-(1-AZA-BICYCLO[2.2.2]OCT-3-YL)-2,3-DIHYDROISOINDOL-l-ONE/5,6-DIHYDRO-FURO[2,3-c]PYRROL-4-ONE DERIVATIVES AS LIGANDS FOR ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR
EA201290255A1 (ru) Способы и композиции для лечения рака
RU2009108280A (ru) Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
MX2010002938A (es) Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
EA200970637A1 (ru) 2-замещенные-6-гетероциклилпроизводные пиримидона в качестве ингибиторов тау-протеинкиназы
NO20080025L (no) Pyrazolderivater som CB1 modulatorer
EA200701856A1 (ru) Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении
MX2023010087A (es) Derivados heterociclicos como inhibidores de cinasas jano.
MX2009008316A (es) Derivados de indol.
HRP20080494T3 (en) Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
RU2008145597A (ru) Гетероциклические арилсульфоны, пригодные для лечения расстройств, которые отвечают на модулирование 5-ht6 рецепторов
BRPI0409374A (pt) composto, composição farmacêutica, uso de pelo menos um composto, e, método para o tratamento de um distúrbio médico
ZA202106014B (en) Solid forms of condensed pyrazines as syk inhibitors